

▼ **This medicinal product is subject to additional monitoring**

Jaydess® (levonorgestrel) 13.5 mg intrauterine delivery system
Prescribing Information

(Refer to full Summary of Product Characteristics (SmPC) before prescribing)

Presentation: Intrauterine delivery system containing 13.5 mg levonorgestrel. **Indication(s):** Contraception for up to 3 years. **Posology & method of administration:** Before insertion exclude pregnancy and sexually transmitted diseases. Insert into the uterine cavity within 7 days of onset of menstruation. Delay postpartum insertions until the uterus is fully involuted and at least 6 weeks after delivery. Jaydess can be inserted immediately after a first trimester termination. Jaydess is effective for 3 years; remove after 3 years use – new system can be inserted at the same time. Jaydess is not indicated in postmenopausal women. **Hepatic impairment:** Jaydess is contraindicated in women with acute liver disease or liver tumour. **Renal impairment:** Jaydess has not been studied in women with renal impairment. **Paediatrics** – Not indicated before menarche. **Contra-indications:** Pregnancy; acute or recurrent pelvic inflammatory disease (PID) or conditions associated with increased risk for pelvic infections; acute cervicitis or vaginitis; postpartum endometritis or infected abortion during past 3 months; cervical intraepithelial neoplasia until resolved; uterine or cervical malignancy; progesterone-sensitive tumours, e.g. breast cancer; abnormal uterine bleeding of unknown etiology; congenital/acquired uterine anomaly including fibroids which would interfere with insertion and / or retention of the system (i.e. if they distort the uterine cavity); hypersensitivity to the active substance or excipients. **Warnings & precautions:** Use with caution after specialist consultation & consider removal if the following exist or arise for the first time: migraine, focal migraine with asymmetrical visual loss or other symptoms indicating transient cerebral ischemia; exceptionally severe headache; jaundice; marked increase of blood pressure; severe arterial disease such as stroke or myocardial infarction. Monitor blood glucose in diabetic users. Inform patient of benefits/risks including signs & symptoms of perforation & risk of ectopic pregnancy. Emphasis should be given to training in the correct insertion technique. Insertion/removal may be associated with pain & bleeding & may result in a vasovagal reaction (e.g. syncope, or a seizure in an epileptic patient). Not recommended for the treatment of heavy menstrual bleeding or protection from endometrial hyperplasia. If a woman becomes pregnant while using Jaydess, the relative likelihood of this pregnancy being ectopic is increased. In clinical trials, the overall incidence of ectopic pregnancy with Jaydess was approximately 0.11 per 100 woman-years. Approximately half of the pregnancies that occur during Jaydess use are likely to be ectopic. Consider ectopic pregnancy if lower abdominal pain occurs, especially with missed periods or if an amenorrhoeic woman starts bleeding –higher risk of ectopic pregnancy for women with previous history of ectopic pregnancy, tubal surgery or pelvic infection. Ectopic pregnancy may impact future fertility so benefits and risk of use should be carefully evaluated, particularly for nulliparous women in whom Jaydess is not first choice for contraception. Irregular bleeding and spotting are common in first months of use. Thereafter, reduction of duration & volume of menstrual bleeding occur as a result of endometrium suppressions. If bleeding becomes heavier and/or more irregular over time use appropriate diagnostic measures as irregular bleeding may be a symptom of endometrial polyps, hyperplasia or cancer & heavy bleeding may be a sign of unnoticed expulsion of Jaydess. As with any IUS/IUD, the highest rate of PID was seen during the first 3 weeks after insertion and decreases thereafter. Although extremely rare, severe infection or sepsis (including group A streptococcal sepsis) can occur following Jaydess insertion. Jaydess must be removed if a woman experiences recurrent endometritis or PID or if an acute infection is severe or does not respond to treatment.

Bacterial examinations & monitoring are recommended even with discrete symptoms indicative of infections. Bleeding, pain increased menstrual flow may indicate partial/complete expulsion. Exclude perforation of uterus or cervix in cases of difficult insertion and/or exceptional pain/bleeding during or after insertion – physical examination may not be sufficient. Such a system must be removed; surgery may be required. Risk of perforation is increased in breast-feeding women, insertions up to 36 weeks post-partum & in women with fixed retroverted uterus. Prescribers should consult the SmPC for further guidance on infection, expulsion or perforation. Ovarian cysts were reported. Advise women to contact their physician in case of mood changes and depressive symptoms, including shortly after initiating treatment. Depression can be serious and is a well-known risk factor for suicidal behaviour and suicide. **Fertility, Pregnancy & breast-feeding:** **Fertility:** Use of Jaydess does not alter the course of future fertility. Upon removal of Jaydess, women return to their normal fertility. **Pregnancy:** If pregnancy

occurs with Jaydess in situ, exclude ectopic pregnancy and remove system. Removal of Jaydess or probing of uterus may result in spontaneous abortion. If woman wishes to continue pregnancy and system cannot be removed, inform her about risks and possible consequences of premature birth to the infant. Monitor pregnancy closely. Instruct woman to report all symptoms suggesting complications of the pregnancy, like cramping abdominal pain with fever. Virilisation effects in female foetus cannot be excluded. There is no evidence of birth defects to date. **Breast-feeding:** About 0.1% of the levonorgestrel dose passes into the breast milk in nursing mothers but no known deleterious effects on infant growth/development.

Undesirable effects: **Very common:** headache, abdominal/pelvic pain, acne/seborrhoea, bleeding changes including increased and decreased menstrual bleeding, spotting, infrequent bleeding and amenorrhoea, ovarian cyst, vulvovaginitis. **Common:** depressed mood/depression, decreased libido, migraine, nausea, alopecia, upper genital tract infection, dysmenorrhoea, breast pain/discomfort, device expulsion (complete and partial), genital discharge, increased weight. **Serious:** cf. *CI/Warnings and Precautions* - in addition: hypersensitivity (incl. urticaria, angioedema). Cases of sepsis (incl. group A streptococcal sepsis) have been reported following IUD insertion. A large post authorisation safety study shows an increased risk of perforation in breast-feeding women or insertions up to 36 weeks post-partum. Prescribers should consult the SmPC in relation to other side effects. **Legal Category:** POM. **Package Quantities and Basic NHS Costs:** £69.22. **MA Number(s):** PL 00010/0587. **Further information available from:** Bayer plc, 400 South Oak Way, Reading, RG2 6AD, United Kingdom. Telephone: 0118 206 3000. **Date of preparation:** July 2020

Jaydess® is a trademark of the Bayer Group

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk> or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc. Tel.: 0118 206 3500, Fax.: 0118 206 3703, Email: pvuk@bayer.com